pp-174 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
Taiwan
GMP approvals
Taiwan
Comments
Indication: Influenza A and B — acute uncomplicated influenza in adults and adolescents
Clinical stage: Phase 3 — ongoing
Modality: Small molecule
Mechanism / Target: Cap-dependent endonuclease (CEN) inhibitor — blocks viral RNA polymerase cap-snatching step required for viral mRNA transcription; same mechanism as baloxavir but structurally distinct
Route / form: Oral tablet (potential single-dose or short course)
Differentiation: Novel CEN inhibitor independent from oseltamivir's neuraminidase mechanism; structurally distinct from baloxavir; potential single-dose convenience; lower resistance risk than neuraminidase inhibitors
Manufacturer #8794
Clinical-stage biotechnology company developing anti-infective and oncology therapeutics. Focuses on single-dose or short-course antiviral agents for influenza and bacterial infections. Wholly owned Phase 3 anti-influenza programme advancing in Asia.
None